On antigen-antibody crossed electrophoresis, the position of the different al-antitrypsin peaks characteristic for the different phenotypes remains the same over a wide range of concentrations. I have followed the al-antitrypsin pattern by antigen-antibody crossed electrophoresis of several heterozygotes for the deficiency gene, when their serum al-antitrypsin was low and when it was high (from 105 to 240 mg/ 100 ml of serum). The position of the peaks did not change; the height of the peaks varied with the concentration of ax-antitrypsin. The precipitation pattern of a heterozygote can be explained by the presence of two groups of electrophoretically distinct but antigenically identical al-antitrypsin components (1) . Although the a1-antitrypsin bands in stained starch gels are usually weak or absent, homozygotes for the deficiency gene have a serum concentration of 25 ± 6 mg/O00 ml (2 
There is no indication of previous observations on monkeys of similar age, no controls to indicate observation of animals handled in identical fashion but without the use of monosodium glutamate, and no quantitative relation to the dose of monosodium glutamate that could be expected to be given to the human infant.
Unless the above questions can be answered, and information can be provided about the effect of monosodium glutamate on passage through the gastrointestinal tract, the report of Olney and Sharpe has no meaning. Lowe and Zavon raise questions concerning specificity of glutamate-induced brain damage, doses, routes of administration, and absorption of glutamate from the gastrointestinal tract. We share their interest in these questions and in order to explore them (1, 2) have conducted experiments in several hundred infant mice. Although not gathered on infant monkeys, these data may be of value in interpreting our infant monkey experiment (3) and in guiding future glutamate research with other preciously scarce primate infants.
In studies designed to investigate specificity and mechanism of action (2), mice (10 days old) were given (by feeding tube) chromatographically pure glutamic acid (4, 5) (1 g/kg); this dose consistently induced a process of necrosis in hypothalamic neurons which was indistinguishable by electron microscopic examination from the neuronal pathology observed in the infant rhesus monkey treated with monosodium glutamate (3). Doses of sodium chloride as high as 8 g/kg (25 times the sodium content of monosodium glutamate at 1.0 g/kg) rendered infant mice nearly prostrate over a 4-hour observation period but resulted in no pathological alterations in hypothalamic or retinal neurons. Monosodium glutarate, which differs from monosodium glutamate only in that it has no amino group, induced no changes in hypothalamic or retinal neurons at 5 g/kg (5) . The majority of amino acids tested induced no detectable changes in hypothalamic or (8) indicate that oral intake of monosodium glutamate in doses of 0.5 to 1 g/kg produces high concentrations of glutamate in the blood, often exceeding 50 mg/100 ml by 15 to 30 minutes but returning to base-line values, in the range of 5 mg/ 100 ml, within 2 hours.
Lowe infers that 2.7 g/kg, the high dose of monosodium glutamate that we administered to test susceptibility in an infant monkey, represents an estimate of lowest effective dose. The only data on lowest effective dose thiat we are aware of are those for the mouse (2). Lowe's 20-jar margin of safety would become much narrower if he were to base his calculations on the lowest effective dose that we found in the infant mouse (0.5 g/kg). Lowe correctly points out that, until recently, some glutamaterich strained baby food (41/2 oz. jars) was supplemented with glutamate (615 mg) (9 
